| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other comprehensive income (loss) | - | - | 211 | - |
| Total other comprehensive (loss) income | -506 | 514 | - | - |
| Net comprehensive income (loss) | 12,393 | 5,599 | 243 | -12,297 |
| Basic net loss per common share (in usd per share) | 0.06 | 0.02 | 0 | -0.07 |
| Diluted net loss per common share (in usd per share) | 0.06 | 0.02 | 0 | -0.07 |
| Weighted average shares outstanding, basic (in shares) | 210,176,000 | 209,519,000 | 208,882,000 | 206,905,000 |
| Weighted average shares outstanding, diluted (in shares) | 219,885,000 | 219,886,000 | 215,261,000 | 206,905,000 |
BIOCRYST PHARMACEUTICALS INC (BCRX)
BIOCRYST PHARMACEUTICALS INC (BCRX)